Advertisement
Screener

Orchestra BioMed Holdings, Inc. (OBIO) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

Orchestra BioMed Holdings, Inc. Stock-Based Compensation

Orchestra BioMed Holdings, Inc. (OBIO) reported Stock-Based Compensation of $5.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-10

  • Orchestra BioMed Holdings, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.50M, a 22.92% decline year-over-year.
  • Orchestra BioMed Holdings, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.85M, a 3.84% decline year-over-year.
  • Orchestra BioMed Holdings, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.75M, a 5.24% decline year-over-year.
  • Orchestra BioMed Holdings, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.01M, a 27.45% increase year-over-year.
  • Orchestra BioMed Holdings, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $11.98M, a 12.84% increase from fiscal 2024.
  • Orchestra BioMed Holdings, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $10.62M, a 39.21% increase from fiscal 2023.
  • Orchestra BioMed Holdings, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $7.63M, a 125.93% increase from fiscal 2022.
  • Orchestra BioMed Holdings, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $3.38M.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 12 month
2026-06-30$2.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
$5.36M
10-Q · filed 2026-08-10
$8.11M
derived: sum of 3 quarters · filed 2026-08-10
$11.12M
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31$2.85M
10-Q · filed 2026-05-12
$5.60M
derived: sum of 2 quarters · filed 2026-05-12
$8.61M
derived: sum of 3 quarters · filed 2026-05-12
$11.86M
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31$2.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$5.76M
derived: sum of 2 quarters · filed 2026-03-12
$9.01M
derived: sum of 3 quarters · filed 2026-08-10
$11.98M
10-K · filed 2026-03-12
2025-09-30$3.01M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$6.26M
derived: sum of 2 quarters · filed 2026-08-10
$9.23M
10-Q · filed 2025-11-10
$12.13M
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30$3.25M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
$6.21M
10-Q · filed 2026-08-10
$9.12M
derived: sum of 3 quarters · filed 2026-08-10
$11.48M
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31$2.96M
10-Q · filed 2026-05-12
$5.87M
derived: sum of 2 quarters · filed 2026-05-12
$8.23M
derived: sum of 3 quarters · filed 2026-05-12
$10.99M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31$2.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$5.27M
derived: sum of 2 quarters · filed 2026-03-12
$8.03M
derived: sum of 3 quarters · filed 2026-03-12
$10.62M
10-K · filed 2026-03-12
2024-09-30$2.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$5.13M
derived: sum of 2 quarters · filed 2025-11-10
$7.71M
10-Q · filed 2025-11-10
$8.63M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30$2.76M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
$5.35M
10-Q · filed 2025-08-12
$6.27M
derived: sum of 3 quarters · filed 2025-08-12
$9.78M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31$2.59M
10-Q · filed 2025-05-12
$3.51M
derived: sum of 2 quarters · filed 2025-05-12
$7.02M
derived: sum of 3 quarters · filed 2025-05-12
$8.72M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31$919.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$4.43M
derived: sum of 2 quarters · filed 2025-03-31
$6.14M
derived: sum of 3 quarters · filed 2025-03-31
$7.63M
10-K · filed 2025-03-31
2023-09-30$3.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$5.22M
derived: sum of 2 quarters · filed 2024-11-12
$6.71M
10-Q · filed 2024-11-12
$7.57M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$1.71M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
$3.20M
10-Q · filed 2024-08-12
$4.06M
derived: sum of 3 quarters · filed 2024-08-12
$6.28M
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31$1.49M
10-Q · filed 2024-05-13
$2.35M
derived: sum of 2 quarters · filed 2024-05-13
$4.58M
derived: sum of 3 quarters · filed 2024-05-13
$4.79M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31$863.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27
$3.09M
derived: sum of 2 quarters · filed 2024-03-27
$3.31M
derived: sum of 3 quarters · filed 2024-03-27
$3.38M
10-K · filed 2024-03-27
2022-09-30$2.22M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
$2.44M
derived: sum of 2 quarters · filed 2023-11-13
$2.51M
10-Q · filed 2023-11-13
2022-06-30$219.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$289.00K
10-Q · filed 2023-08-10
2022-03-31$70.00K
10-Q · filed 2023-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
SHOULDER INNOVATIONS, INC. (SI)United States$0.355B
Orthofix Medical Inc. (OFIX)$0.373B
Embecta Corp. (EMBC)United States$0.319B2.10
CARLSMED, INC. (CARL)United States$0.405B
TREACE MEDICAL CONCEPTS, INC. (TMCI)United States$0.297B-4.32
Mobia Medical, Inc. (MOBI)United States$0.293B
TriSalus Life Sciences, Inc. (TLSI)United States$0.283B-9.92
Cytosorbents Corp (CTSO)United States$0.274B-1.29
ORASURE TECHNOLOGIES INC (OSUR)United States$0.272B-6.26
Anika Therapeutics, Inc. (ANIK)United States$0.272B-51.71